scholarly journals Exatecan Mesylate Anhydrous

2020 ◽  
Author(s):  
Keyword(s):  
Exatecan Mesylate

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4006-4006 ◽  
Author(s):  
E. M. O' Reilly ◽  
G. K. Abou-Alfa ◽  
R. Letourneau ◽  
W. G. Harker ◽  
M. Modiano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Exatecan Mesylate

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2069-2069
Author(s):  
C. J. Sweeney ◽  
M. W. Saif ◽  
P. M. Lorusso ◽  
M. P. Ducharme ◽  
R. Demnati ◽  
...  
Keyword(s):  
Phase I ◽  
Renal Dysfunction ◽  
Phase I Study ◽  
Exatecan Mesylate

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4006-4006 ◽  
Author(s):  
E. M. O' Reilly ◽  
G. K. Abou-Alfa ◽  
R. Letourneau ◽  
W. G. Harker ◽  
M. Modiano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Exatecan Mesylate

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2069-2069 ◽  
Author(s):  
C. J. Sweeney ◽  
M. W. Saif ◽  
P. M. Lorusso ◽  
M. P. Ducharme ◽  
R. Demnati ◽  
...  
Keyword(s):  
Phase I ◽  
Renal Dysfunction ◽  
Phase I Study ◽  
Exatecan Mesylate

Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog

2001 ◽  
Vol 19 (5) ◽  
pp. 1493-1500 ◽  
Author(s):  
Melanie E. Royce ◽  
Paulo M. Hoff ◽  
Pamela Dumas ◽  
Yvonne Lassere ◽  
J. Jack Lee ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase Ii ◽  
Performance Status ◽  
Maximum Tolerated Dose ◽  
Volume Of Distribution ◽  
Hematologic Toxicity ◽  
Heavily Pretreated ◽  
Pretreated Patients ◽  
Exatecan Mesylate ◽  
Recommended Phase Ii Dose

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic (PK) profile, and recommended phase II dose of Exatecan mesylate (DX-8951f) when administered as a 24-hour continuous infusion every 3 weeks to patients with solid tumors. PATIENTS AND METHODS: Twenty-two patients with advanced solid tumors, all previously treated, and with performance status ≤ 2, were entered. The starting dose of DX-8951f was 0.15 mg/m2; the dose was escalated according to the modified continual reassessment method. The drug was administered until disease progression or until unacceptable toxic effects occurred. RESULTS: Seven dose escalations were completed, and a total of 53 courses were delivered (median, two courses; range, one to eight courses) during the study. At doses 1.2 mg/m2 and lower, toxicities were mostly grade 1, primarily hematologic. In the initial cohort of three patients treated at 2.4 mg/m2, grade 2 hematologic toxicity was observed. Of the six additional patients entered at 2.4 mg/m2, three had grade 3 or 4 granulocytopenia. At doses higher than 2.4 mg/m2, DLT granulocytopenia was observed. Nonhematologic toxicities, including nausea, vomiting, diarrhea, fatigue, and alopecia, were mild to moderate. Neither complete nor partial responses were observed, but four patients had stable disease. The PK profile of DX-8951f seemed linear at the doses administered. The plasma clearance, total volume of distribution, and terminal elimination half-life were approximately 3 L/h, 40 L, and 14 hours, respectively. CONCLUSION: The DLT of this DX-8951f schedule was granulocytopenia for minimally pretreated patients, and both granulocytopenia and thrombocytopenia for heavily pretreated patients. The MTD for both minimally and heavily pretreated patients was 2.4 mg/m2. DX-8951f seems to have a linear PK profile on the basis of single-dose administration. The recommended phase II dose with this schedule is 2.4 mg/m2 for minimally pretreated patients. A lower dose should be used for heavily pretreated patients.

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

Lung Cancer ◽  
2003 ◽  
Vol 41 (2) ◽  
pp. 215-219 ◽  
Author(s):  
J.P Braybrooke ◽  
M Ranson ◽  
C Manegold ◽  
K Mattson ◽  
N Thatcher ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Exatecan Mesylate

Phase II study of Exatecan Mesylate (DX-8951f) in advanced NSCLC

Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 55
Author(s):  
D.C Talbot ◽  
S White ◽  
K.V Mattson ◽  
C Manegold ◽  
P Jones ◽  
...  
Keyword(s):  
Phase Ii ◽  
Advanced Nsclc ◽  
Phase Ii Study ◽  
Exatecan Mesylate
Sign in / Sign up

Export Citation Format

Share Document